Lv11
60 积分 2023-01-28 加入
Degrader–Antibody Conjugates: Emerging New Modality
5小时前
已完结
An updated patent review of BRD4 degraders
5天前
已完结
Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor
24天前
已关闭
Homogeneous multi-payload antibody–drug conjugates
1个月前
已完结
Dual-Action-Only PROTACs
1个月前
已完结
Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity
3个月前
已完结
Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
4个月前
已完结
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
6个月前
已完结
BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review
6个月前
已完结
Linker and Conjugation Site Synergy in Antibody–Drug Conjugates: Impacts on Biological Activity
6个月前
已完结
皖公网安备34019202002308
